These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

943 related items for PubMed ID: 17697543

  • 1. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ.
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [Abstract] [Full Text] [Related]

  • 2. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB.
    Clin Cancer Res; 2008 Jul 15; 14(14):4650-7. PubMed ID: 18628480
    [Abstract] [Full Text] [Related]

  • 3. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.
    Exp Hematol; 2010 Mar 15; 38(3):213-21. PubMed ID: 20056126
    [Abstract] [Full Text] [Related]

  • 4. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez-Sánchez JL, Sierra J, Briones J.
    Exp Hematol; 2008 Jan 15; 36(1):69-77. PubMed ID: 17959301
    [Abstract] [Full Text] [Related]

  • 5. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 6. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
    Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, Carter-Brookins D, Newton S, Flinn IW.
    Clin Cancer Res; 2007 Apr 15; 13(8):2392-9. PubMed ID: 17438098
    [Abstract] [Full Text] [Related]

  • 7. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.
    J Immunother; 2007 Jan 15; 30(1):64-74. PubMed ID: 17198084
    [Abstract] [Full Text] [Related]

  • 8. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 15; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 9. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
    Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, Rambaldi A, Introna M.
    Haematologica; 2003 Sep 15; 88(9):1002-12. PubMed ID: 12969808
    [Abstract] [Full Text] [Related]

  • 10. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
    Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6101-10. PubMed ID: 15447996
    [Abstract] [Full Text] [Related]

  • 11. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
    Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E, Uharek L.
    Exp Hematol; 2006 Jun 15; 34(6):753-9. PubMed ID: 16728280
    [Abstract] [Full Text] [Related]

  • 12. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

  • 13. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ.
    Exp Hematol; 2007 Dec 01; 35(12):1801-11. PubMed ID: 17681667
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S, Emmanouilides C, Bonavida B.
    Clin Cancer Res; 2001 Mar 01; 7(3):709-23. PubMed ID: 11297268
    [Abstract] [Full Text] [Related]

  • 15. [Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].
    Zhang WX, Guo J, Lin BH, Meng SN, Wang XP, Xie Y, Zheng W, Zhang YT, Zhu J.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan 01; 28(1):41-4. PubMed ID: 17649726
    [Abstract] [Full Text] [Related]

  • 16. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW, Shamim F, Hamon M, Macdonald ID, Prentice HG.
    Exp Hematol; 1995 Dec 01; 23(14):1530-4. PubMed ID: 8542943
    [Abstract] [Full Text] [Related]

  • 17. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 24; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
    Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef IN, Stella P, Etzell P, Novak AJ, Erlichman C, Witzig TE.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6056-63. PubMed ID: 17062681
    [Abstract] [Full Text] [Related]

  • 20. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
    Markasz L, Vanherberghen B, Flaberg E, Otvös R, Stuber G, Gustafsson Jernberg A, Olah E, Skribek H, Szekely L.
    Biomed Pharmacother; 2009 Jul 15; 63(6):413-20. PubMed ID: 18834693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.